scholarly journals A RARE HISTOLOGICAL FINDING AFTER PANCREATICODUODENECTOMY

2021 ◽  
Vol 20 (2) ◽  
pp. 136-140
Author(s):  
V. Y. Rayn ◽  
M. A. Persidskiy ◽  
V. P. Ionin ◽  
E. D. Khadieva
Keyword(s):  
Malignant Tumors ◽  
Histological Finding ◽  
Pancreatic Head ◽  
Immunohistochemical Analysis ◽  
Resection Margins ◽  
Tumor Diameter ◽  
Duodenal Papilla ◽  
Neuroendocrine Cancer ◽  
Major Duodenal Papilla ◽  
Cytokeratin 5

In this paper, we describe the case of successful surgical treatment of a rare combination of three malignant tumors of the major duodenal papilla in one patient. A 59-year-old woman presented with abdominal pain, fever, nausea, vomiting, weight loss and obstructive jaundice. After routine examination, the patient with suspected cancer of the major duodenal papilla underwent pylorus-sparing pancreatoduodenal resection. Final histology revealed a rare collision of three types of cancer in the major duodenal papilla invading the pancreatic head: moderately-differentiated adenocarcinoma (30 %), moderately differentiated squamous cell carcinoma (20 %) and poorly differentiated small cell neuroendocrine cancer (50 %), surgical resection margins were intact. Immunohistochemical analysis revealed positivity for synaptophysin, chromogranin A and cytokeratin 5/6. The tumor diameter of 2 cm and the absence of signs of locoregional spread allowed the process to be staged as T2N0M0, so the patient did not receive any adjuvant treatment. Follow-up CT performed 6 months later showed two lesions in the liver, and biopsy of one of them was performed. Metastasis of neuroendocrine cancer was histologically and immunohistochemically verified. She started first-line chemotherapy with etoposide + cisplatin.

Prognostic Factors in the Operative Management of Dedifferentiated Sacral Chordomas

Neurosurgery ◽  
2014 ◽  
Vol 75 (3) ◽  
pp. 269-275 ◽  
Author(s):  
Babar Kayani ◽  
Mathew D. Sewell ◽  
Sammy A. Hanna ◽  
Asif Saifuddin ◽  
William Aston ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Local Recurrence ◽  
Sacroiliac Joint ◽  
De Novo ◽  
Malignant Tumors ◽  
Spinal Tumors ◽  
Resection Margins ◽  
Tumor Diameter ◽  
Increased Risk

Abstract BACKGROUND: Dedifferentiated chordomas are rare high-grade malignant spinal tumors for which there is minimal information to help guide treatment. OBJECTIVE: To identify prognostic factors associated with increased risk of local recurrence, metastases, and reduced survival in a cohort of patients undergoing sacrectomy for de novo dedifferentiated sacral chordoma. METHODS: Ten patients undergoing sacrectomy for histologically confirmed dedifferentiated chordoma at a specialist center were reviewed. There were 6 male and 4 female patients with a mean age of 66.7 years (range, 57-80 years) and mean follow-up of 36.7 months (range, 3-98 months). Data on prognostic factors were collected. RESULTS: The commonest presenting symptom was lumbar/gluteal pain. Mean duration of preoperative symptoms was 3.6 months (range, 2-7 months). Local recurrence was seen in 7 patients; metastases occurred in 5 patients. After sacrectomy, 7 patients died at a mean of 41 months (range, 3-98 months). Tumor size >10 cm in diameter, amount of dedifferentiation within the conventional chordoma, sacroiliac joint infiltration, and inadequate resection margins were associated with increased risk of recurrence and reduced survival. Surgical approach, cephalad extent of primary tumor, and adjuvant radiotherapy did not affect oncological outcomes. CONCLUSION: Dedifferentiated chordomas are aggressive malignant tumors with a higher risk of local recurrence, metastases, and early mortality than conventional chordomas. Tumor diameter >10 cm, marginal resection, and sacroiliac joint infiltration may be associated with increased risk of local recurrence and mortality. Those with a smaller burden of dedifferentiated disease (<1 cm2) within the primary chordoma have a better prognosis. Patients should be counseled about these risks before surgery and should have regular follow-up for the detection of local recurrence and metastases.

Clinical case of palliative antegrade surgical treatment of cancer of the major duodenal papilla

2016 ◽  
Vol 21 (5) ◽  
pp. 244-249
Author(s):  
Yury S. Vinnik ◽  
E. V Serova ◽  
D. A Chernykh ◽  
A. V Kovalev ◽  
D. V Stratovich ◽  
...  
Keyword(s):  
Bile Duct ◽  
Common Bile Duct ◽  
Obstructive Jaundice ◽  
Biliary Tract ◽  
Malignant Tumors ◽  
Internal Drainage ◽  
Duodenal Papilla ◽  
Major Duodenal Papilla ◽  
Duct Cancer ◽  
The Common

In the structure of malignant tumors, accompanied by obstructive jaundice, there are most occurred such as the lesion of the pancreas (47%), bile duct cancer (20%) also papillary carcinoma (MDP) and gall bladder cancer (about 15%). In the case of inoperable tumor, in elderly and senile patients with severe concomitant somatic pathology, there are indicated palliative interventions as follows: percutaneous transhepatic external or external-internal drainage of the biliary tract with possible subsequent percutaneous transhepatic stenting of the common bile duct. Under our observation there was a patient of 75 years with verified major duodenal papilla cancer, complicated by obstructive jaundice, to whom as the first step there was performed percutaneous transhepatic external-internal drainage of the biliary tract, and as the second one - percutaneous transhepatic stenting of the common bile duct.

Primary stromal sarcoma of breast: A case report and literature review

2021 ◽  
pp. 1-7
Author(s):  
Mohammad Al-Wiswasy ◽  
Mahmoud Al-Balas ◽  
Raith Al-Saffar ◽  
Hamzeh Al-Balas
Keyword(s):  
Malignant Tumors ◽  
Histopathological Examination ◽  
Prognostic Significance ◽  
Total Duration ◽  
Young Patients ◽  
Soft Tissue Sarcomas ◽  
Breast Mass ◽  
Resection Margins ◽  
Stromal Sarcoma ◽  
First Case

INTRODUCTION: Primary breast sarcoma (PBS) was first described in 1887 as a rare heterogeneous neoplasm arising from the mesenchymal tissue of the mammary gland accounting for less than 5% of all body soft-tissue sarcomas and less than 0.1% of all malignant tumors of the breast. CASE PRESENTATION: A 31-year old lady presented with left breast mass which she felt four years before during which the mass increased in size from 1 to 6 cm in the largest diameter, diagnosed clinically as a benign fibroadenoma without any further cytological or histopathological confirmation. Histopathological examination of the excised breast mass reveals undifferentiated, primary stromal sarcoma of the breast (PSSB), which was followed by mastectomy three weeks later with reconstructive breast surgery with a total duration of follow-up of 3 years thereafter. This is the first case of PSSB reported in Jordan. DISCUSSION/CONCLUSION: PSSB is the generic term given to malignant breast tumors thought to arise from the specialized mesenchymal stroma of the breast but lacking an epithelial component with a phylloides pattern. PSSB is difficult to diagnose preoperatively due to its rarity and inadequate imaging methods to establish an exact diagnosis. The histology of the patient mass may be the leading factor for the management of these tumors. Even in very young patients, a progressively growing breast mass should alert the clinician to investigate for malignancy and verify the results by biopsy. Surgery with adequate resection margins represents the only potentially curative modality with prognostic significance. Adjuvant chemotherapy and radiotherapy are not very beneficial. The prognosis is dismal for patients with lymph node involvement and the size of the tumor has a lesser bearing on the outcome.

scholarly journals Aspartame and cancer – new evidence for causation

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Philip J. Landrigan ◽  
Kurt Straif
Keyword(s):  
Public Health ◽  
Cancer Risk ◽  
Malignant Tumors ◽  
Daily Intake ◽  
Immunohistochemical Analysis ◽  
International Agency ◽  
Advisory Group ◽  
Malignant Neoplasms ◽  
Acceptable Daily Intake ◽  
New Findings

Abstract Background Aspartame is one of the world’s most widely used artificial sweeteners and is an ingredient in more than 5000 food products globally. A particularly important use is in low-calorie beverages consumed by children and pregnant women. The Ramazzini Institute (RI) reported in 2006 and 2007 that aspartame causes dose-related increases in malignant tumors in multiple organs in rats and mice. Increased cancer risk was seen even at low exposure levels approaching the Acceptable Daily Intake (ADI). Prenatal exposures caused increased malignancies in rodent offspring at lower doses than in adults. These findings generated intense controversy focused on the accuracy of RI’s diagnoses of hematopoietic and lymphoid tissue tumors (HLTs). Critics made the claim that pulmonary lesions observed in aspartame-exposed animals were inflammatory lesions caused by Mycoplasma infection rather than malignant neoplasms. Methods To address this question, RI subjected all HLTs from aspartame-exposed animals to immunohistochemical analysis using a battery of markers and to morphological reassessment using the most recent Internationally Harmonized Nomenclature and Diagnostic (INHAND) criteria. Findings This immunohistochemical and morphological re-evaluation confirmed the original diagnoses of malignancy in 92.3% of cases. Six lesions originally diagnosed as lymphoma (8% of all HLTs) were reclassified: 3 to lymphoid hyperplasia, and 3 to chronic inflammation with fibrosis. There was no evidence of Mycoplasma infection. Interpretation These new findings confirm that aspartame is a chemical carcinogen in rodents. They confirm the very worrisome finding that prenatal exposure to aspartame increases cancer risk in rodent offspring. They validate the conclusions of the original RI studies. These findings are of great importance for public health. In light of them, we encourage all national and international public health agencies to urgently reexamine their assessments of aspartame’s health risks - especially the risks of prenatal and early postnatal exposures. We call upon food agencies to reassess Acceptable Daily Intake (ADI) levels for aspartame. We note that an Advisory Group to the International Agency for Research on Cancer has recommended high-priority reevaluation of aspartame’s carcinogenicity to humans.

GCSF As a Potential Molecular Target for Overall Survival of Hepatocellular Carcinoma

2021 ◽  
Vol 24 ◽  
Author(s):  
Heng Cao ◽  
Peng Guo ◽  
Xiaohui Wu ◽  
Jiankun Li ◽  
Chenlong Ge ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Survival Analysis ◽  
Molecular Mechanisms ◽  
Malignant Tumors ◽  
Basic Research ◽  
Clinical Samples ◽  
Tumor Diameter ◽  
Overall Survival Analysis

Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of digestive tract in the world. Therefore, it is important to carry out studies on the molecular mechanisms of early diagnosis and treatment of HCC to reduce mortality. Methods: Bioinformatic analysis was performed to explore the significant role of GCSF on the occurrence and development of neoplasm. Differently expressed genes (DEGs) were screened, and the significant hub genes related with GCSF were identified by the multiple algorithms of Cytoscape. Functional annotation for DEGs, pathological stage and overall survival analysis were implemented. In addition, the verification for the role of GCSF on HCC was made via the clinical samples. A total of 70 participates diagnosed as HCC were recruited from November 2014 to November 2019. The immunohistochemistry assay, qRT-PCR, receiver operating characteristic (ROC) curves, and overall survival analysis were carried out. Results: GCSF was related with the tumor size, and the expression of GCSF was up-regulated in hepatocellular carcinoma tissues. The enrichment results of GO and KEGG analysis were mainly enriched in “Inflammatory response”, “Protein binding”, “Metabolic pathways”, and “Proteasome”. The tumor diameter (P < 0.001), and survival time (P < 0.001) were significantly associated with expression of GCSF via the verification of clinical data. The univariate and multivariate Cox proportional regression analysis manifested that high expression of GCSF in patients with HCC was related to poor OS. Conclusion: The expression level of GCSF is significantly associated with the prognostic survival of HCC, and it is expected to become a new prognostic marker of HCC, providing a novel idea for future basic research as well as targeted therapy.

scholarly journals Abstract No. 228 EE: Duodenal stenting over the major duodenal papilla using a transhepatic approach

2010 ◽  
Vol 21 (2) ◽  
pp. S87-S88
Author(s):  
L.N. Boucher ◽  
C. Dey ◽  
R. Gadahadh ◽  
T. Cabrera ◽  
N. Khattar ◽  
...  
Keyword(s):  
Duodenal Papilla ◽  
Major Duodenal Papilla

Laparoscopic duodenum-preserving total pancreatic head resection: a novel surgical approach for benign or low-grade malignant tumors

2018 ◽  
Vol 33 (2) ◽  
pp. 633-638 ◽  
Author(s):  
Jun Cao ◽  
Guo-lin Li ◽  
Jin-xing Wei ◽  
Wei-Bang Yang ◽  
Chang-zhen Shang ◽  
...  
Keyword(s):  
Surgical Approach ◽  
Malignant Tumors ◽  
Pancreatic Head ◽  
Low Grade ◽  
Pancreatic Head Resection

scholarly journals Acinar cell cystadenoma of the pancreatic head

2020 ◽  
Vol 25 (2) ◽  
pp. 145-151
Author(s):  
A. V. Shabunin ◽  
М. М. Tavobilov ◽  
A. A. Karpov ◽  
О. V. Paklina ◽  
G. R. Setdikova ◽  
...  
Keyword(s):  
Acinar Cell ◽  
Clinical Case ◽  
Pancreatic Head ◽  
Immunohistochemical Analysis ◽  
Pancreatic Tumors ◽  
Routine Examination ◽  
Benign Pancreatic Tumors ◽  
Adjacent Structures ◽  
Benign Nature ◽  
Surgical Tactics

Acinar cell cystadenoma is one of the rarest benign pancreatic tumors. A clinical case of acinar cell cystadenoma of the pancreatic head in a 67-year-old patient is presented. The tumor was detected during a routine examination. The patient was undergoing surgery, enucleation of the neoplasm was performed. With a planned histologic examination and immunohistochemical analysis the diagnosis was confirmed. Surgical tactics depend on the location, size of the tumor and position to the adjacent structures. Given the benign nature of tumor, preference should be given to organpreserving interventions.

scholarly journals Chondrosarcoma of the Nasal Septum—A Rare Subsite: Case Report with Review of Literature

2021 ◽  
Vol 42 (05) ◽  
pp. 506-509
Author(s):  
Nidhi Gupta ◽  
Awadhesh Kumar Pandey ◽  
Kislay Dimri ◽  
Surinder K Singhal ◽  
Neeraj Rathee ◽  
...  
Keyword(s):  
Nasal Septum ◽  
Malignant Tumors ◽  
Surgical Excision ◽  
Metastatic Potential ◽  
Young Female ◽  
Resection Margins ◽  
Diagnostic Dilemma ◽  
Complete Surgical Excision ◽  
Grade Ii ◽  
Common Primary Malignant Bone

AbstractChondrosarcomas are the second most common primary malignant bone tumors. Head and neck chondrosarcomas constitute less than 10% of these tumors, rarely arising from the nasal septum. These are locally aggressive malignant tumors arising from the cartilaginous framework of the nasal septum. Rarity of the tumor coupled with nonspecific symptoms makes it a diagnostic dilemma. Diagnosis requires endoscopy, radiology, and final histopathology for confirmation. Treatment is mainly surgical, requiring complete surgical excision with clear margins. Radiation has a role in unresectable tumors or for tumors with positive margins after surgery. Survival depends on the grade of tumor that predicts the metastatic potential of the tumor. We present a rare case of chondrosarcoma arising from the nasal septum in a 29-year-old young female presenting with complaints of nasal obstruction. Computed tomography was suggestive of a calcified cartilaginous tumor arising from the nasal septum. Endoscopic excision was done and postoperative histopathology showed grade II chondrosarcoma with clear margins. No adjuvant treatment was given to our patient and 2 years post-excision patient is disease free.To conclude, chondrosarcoma of the nasal septum is a rare tumor, with nonspecific symptoms. Surgery with clear margins remains the treatment of choice. Prognosis depends on the extent of tumor at presentation, resection margins, and grade of tumor.

scholarly journals A Case of Choriocarcinoma of the Major Duodenal Papilla

2010 ◽  
Vol 43 (11) ◽  
pp. 1129-1133
Author(s):  
Yasunori Kurahashi ◽  
Yoshiharu Shirakata ◽  
Koji Hirata ◽  
Hisashi Shinohara ◽  
Kazumi Itoi ◽  
...  
Keyword(s):  
Duodenal Papilla ◽  
Major Duodenal Papilla
Sign in / Sign up

Export Citation Format

Share Document